Terumo Penpol

Terumo Donates Additional USD 1 Million to Support the COVID-19 Solidarity Response Fund for WHO

Retrieved on: 
Friday, May 14, 2021

Terumo has already donated USD 1 Million in April 2020 , and this is the company\'s second time contributing to the fund.\nThe fund, managed by the WHO Foundation, marked its first anniversary this March.

Key Points: 
  • Terumo has already donated USD 1 Million in April 2020 , and this is the company\'s second time contributing to the fund.\nThe fund, managed by the WHO Foundation, marked its first anniversary this March.
  • Vaccine administrations have begun across the world,yet low-income countries have received less than 1% of all of the vaccines administered worldwide.
  • Based in Tokyo and operating globally, Terumo employs more than 25,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions.
  • Terumo will further strive to be of value to patients, medical professionals, and society at large.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/terumo-donates-additional-usd-1-...\n'

Terumo Donates Additional USD 1 Million to Support the COVID-19 Solidarity Response Fund for WHO

Retrieved on: 
Friday, May 14, 2021

Terumo has already donated USD 1 Million in April 2020 , and this is the company\'s second time contributing to the fund.\nThe fund, managed by the WHO Foundation, marked its first anniversary this March.

Key Points: 
  • Terumo has already donated USD 1 Million in April 2020 , and this is the company\'s second time contributing to the fund.\nThe fund, managed by the WHO Foundation, marked its first anniversary this March.
  • Vaccine administrations have begun across the world,yet low-income countries have received less than 1% of all of the vaccines administered worldwide.
  • Based in Tokyo and operating globally, Terumo employs more than 25,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions.
  • Terumo will further strive to be of value to patients, medical professionals, and society at large.\n'

Terumo Acquires Quirem Medical to Enhance Its Interventional Oncology Field

Retrieved on: 
Wednesday, July 15, 2020

Under the terms of the agreement, Terumo acquired 80.1% of the shares of Quirem Medical.

Key Points: 
  • Under the terms of the agreement, Terumo acquired 80.1% of the shares of Quirem Medical.
  • This is over and above its current share position of 19.9%, making Quirem Medical now a wholly owned subsidiary of Terumo.
  • Quirem Medical has developed and manufactures QuiremSpheres, the only commercially available microspheres containing the radioactive isotope Holmium-166.
  • In 2015, Terumo invested in Quirem Medical and became the exclusive global distributor of their technology.